PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVenlafaxine
Venlafaxine
Effexor, Venlafaxine (venlafaxine) is a small molecule pharmaceutical. Venlafaxine was first approved as Effexor on 1993-12-28. It is used to treat attention deficit disorder with hyperactivity, autistic disorder, chronic fatigue syndrome, depressive disorder, and obsessive-compulsive disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
mental disordersD001523
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Effexor, Venlafaxine, Venlafaxine besylate (discontinued: Effexor, Venlafaxine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Venlafaxine hydrochloride
Tradename
Company
Number
Date
Products
VENLAFAXINE HYDROCHLORIDERVL PharmaceuticalsN-022104 RX2008-05-20
4 products, RLD
EFFEXOR XRUpjohnN-020699 RX1997-10-20
3 products, RLD, RS
Show 2 discontinued
Venlafaxine besylate
Tradename
Company
Number
Date
Products
VENLAFAXINE BESYLATEAlmatica PharmaN-215429 RX2022-06-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
New Drug Application2009-10-27
effexorNew Drug Application2023-08-15
effexor xr2008-12-03
venlafaxineANDA2025-09-26
venlafaxine hclANDA2024-12-31
venlafaxine hcl erANDA2025-01-22
venlafaxine hydrochlorideANDA2025-10-02
venlafaxine hydrochloride, extended releaseANDA2024-01-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
chronic fatigue syndromeEFO_0004540D015673G93.31
attention deficit disorder with hyperactivityEFO_0003888D001289F90
obsessive-compulsive disorderEFO_0004242D009771F42
depressive disorderEFO_1002014D003866F32.A
autistic disorderEFO_0003758D001321F84.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Venlafaxine Besylate, Venlafaxine Besylate, Almatica
77763582028-05-16DP
67170152023-03-27DS, DPU-451
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX16: Venlafaxine
HCPCS
No data
Clinical
Clinical Trials
265 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———5————5
MalnutritionD044342EFO_0008572E40-E461————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVenlafaxine
INNvenlafaxine
Description
Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. It has a role as an antidepressant, a serotonin uptake inhibitor, an adrenergic uptake inhibitor, a dopamine uptake inhibitor, an analgesic, an environmental contaminant and a xenobiotic. It is a member of cyclohexanols, a tertiary alcohol, a tertiary amino compound and a monomethoxybenzene.
Classification
Small molecule
Drug classantianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
Identifiers
PDB—
CAS-ID93413-69-5
RxCUI—
ChEMBL IDCHEMBL637
ChEBI ID9943
PubChem CID5656
DrugBankDB00285
UNII IDGRZ5RCB1QG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Effexor – Viatris
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Effexor – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Venlafaxine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 19,434 documents
View more details
Safety
Black-box Warning
Black-box warning for: Effexor, Effexor xr, Venlafaxine, Venlafaxine hcl, Venlafaxine hcl er, Venlafaxine hydrochloride, Venlafaxine hydrochloride, extended release
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
85,365 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use